|
|
Volumn 6, Issue 1, 2006, Pages 1-
|
|
Who should be vaccinated against human papillomavirus?
[No Author Info available]
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
NEUTRALIZING ANTIBODY;
PROTEIN L1;
UNCLASSIFIED DRUG;
VIRUS PROTEIN;
WART VIRUS VACCINE;
CANCER MORTALITY;
CANCER PREVENTION;
CLINICAL TRIAL;
DRUG APPROVAL;
DRUG EFFICACY;
EDITORIAL;
HERD IMMUNITY;
HUMAN;
HUMAN PAPILLOMAVIRUS TYPE 11;
HUMAN PAPILLOMAVIRUS TYPE 16;
HUMAN PAPILLOMAVIRUS TYPE 18;
HUMAN PAPILLOMAVIRUS TYPE 6;
POSTMARKETING SURVEILLANCE;
PRIORITY JOURNAL;
TUMOR IMMUNITY;
UTERINE CERVIX CANCER;
VACCINATION;
VIRUS PARTICLE;
WART VIRUS;
CLINICAL TRIALS, PHASE III;
FEMALE;
HEALTH POLICY;
HUMANS;
MALE;
PAPILLOMAVIRIDAE;
PAPILLOMAVIRUS INFECTIONS;
UTERINE CERVICAL NEOPLASMS;
VACCINATION;
VIRAL VACCINES;
|
|
EID: 29244434527
PISSN: 14733099
EISSN: None
Source Type: Journal
DOI: 10.1016/S1473-3099(05)70301-7 Document Type: Editorial |
|
Times cited : (11)
|
|
References (0)
|